期刊文献+

冠心病患者分泌型磷脂酶A2的变化及其与白细胞介素8、溶血磷脂酸的关系 被引量:4

Elevated serum secretory typeⅡphospholipase A2 in patients with coronary heart disease
原文传递
导出
摘要 目的了解冠心病患者分泌型磷脂酶 A2(sPLA2)的变化,并通过测定 IL-8、LPA 等相关细胞因子,对 sPLA2的作用机制进行初步探讨。方法冠状动脉造影确诊的262例患者,其中急性冠脉综合征(ACS)110例,稳定性冠心病(SCHD)63例,正常患者89例,分别测定 sPLA2、白细胞介素8(IL-8)、高敏 C 反应蛋白(hs-CRP)和溶血磷脂酸(LPA)水平,并进行对比分析。结果冠心病患者sPLA2[(68±17)U/ml]、IL-8[(182±80)pg/ml]以及 LPA[(2.85±0.36)μmol/L]均明显高于对照组[sPLA2:(55±12)U/ml,IL-8:(119±33)pg/ml,LPA:(2.34±0.36)μmol/L,均 P<0.01],其中ACS 组的 sPLA2[(71±18)U/ml]、IL-8[(195±78)pg/ml]也明显高于 SCHD 组[sPLA2:(63±12)U/ml],IL-8:[(159±79)pg/ml,均 P<0.01;sPLA2与 IL-8(r=0.203,P=0.007)、LPA(r=0.658,P<0.01)、hs-CRP(r=0.231,P=0.005)均呈正相关;sPLA2≥63.75 U/ml 时,患冠心病的相对危险度为6.248(P<0.01)。结论冠心病患者 sPLA2明显升高,它可能与 IL-8共同参与冠心病的炎症发展过程,并与下游相关产物 LPA 进一步加速其进展。提示 sPLA2升高是冠心病的独立危险因素之一。 Objective To measure the serum level of secretory type Ⅱ phospholipase A2 (sPLA2) in patients with coronary heart disease and investigate the possible relationship with IL-8 and LPA. Methods A total of 110 patients with acute coronary syndrome (ACS), 63 patients with stable coronary heart disease (SCHD) group and 89 non-CHD control patients were studied. Serum levels of sPLA2, IL-8, LPA and hs- CRP were measured and the correlation among these parameters was observed. Results The levels of serum sPLA2 [ (68 ± 17 ) U/ml ], IL-8 [ ( 182 ± 80 ) pg/ml ] and LPA [ (2. 85 ± 0. 36 ) μmol/L ] were significantly higher in CHD patients than those in controls [ sPLA2 : ( 55 ± 12 ) U/ml; IL-8 : ( 119 ±33 ) pg/ml; LPA: (2. 34 ±0. 36)μmol/L, all P 〈0. 01 ], and sPLA2 and IL-8 were also significantly higher in ACS patients [sPLA2:(71 ±18) U/ml; IL-8:(195 ±78) pg/ml] than those in SCHD patients [sPLA2:(63 ±12) U/ ml ; IL-8 : ( 159 ± 79 ) pg/ml, both P 〈 0.01 ]. Serum sPLA2 level was positively correlated with hs-CRP, IL-8 and LPA ( r = 0. 203, P = 0. 007 ; r = 0. 658, P 〈 0. 01 ; r = 0. 231, P = 0. 005, respectively). The relative risk of having CHD is 6. 248 ( P 〈 0.01 ) with the sPLA2 level above 63. 75 U/ml. Conclusion Elevated serum sPLA2 level is a risk factor for CHD.
出处 《中华心血管病杂志》 CAS CSCD 北大核心 2006年第9期812-815,共4页 Chinese Journal of Cardiology
基金 浙江省科学技术基金(20004C33045) 卫生部国际交流中心默沙东科研基金(419056-X10101)
关键词 冠状动脉疾病 白细胞介素8 溶血磷脂酸 分泌型磷脂酶A2 Coronary disease Interleukin-8 Lysophosphatidic acid Type Ⅱ secretory phospholipase A2
  • 相关文献

参考文献8

  • 1Masuda S,Murakami M,Komiyama K,et al.Various secretory poospholipase A2 enzymes are expressed in rheumatoid arthritis and augment prostaglandin production in cultured synovial cells.FEBS J,2005,272:655-672.
  • 2Dullemen H,Wolbink G,Wever P,et al.Reduction of circulating secretory phospholipase A2 levels by anti-tumor necrosis factor chimeric monoclonal antibody in patients with severe Crohn's disease.Relation between tumor necrosis factor and secretory phospholipase A2 in healthy humans and in active Crohn's disease.Scand JGastroenterol,1998,33:1094-1098.
  • 3Ghesquiere S,Gijbels M,Anthonsen M,et al.Macrophage-specific overexpression of group Ⅱ a sPLA2 increases atherosclerosis and enhances collagen deposition.J Lipid Res,2005,46:201-210.
  • 4Hurt-Camejo E,Camejo G,Sartipy P,et al.Phospholipase A2 and small,dense low-density lipoprotein.Curr Opin Lipidol,2000,11:465 -471.
  • 5Niessen HW,Krijnen PA,Visser CA,et al.Type Ⅱ secretory phospholipase A2 in cardiovascular disease:a mediator in atherosclerosis and ischemic damage to cardiomyocytes? Cardiovasc Res,2003,60:68-77.
  • 6Ozeren A,Aydin M,Tokac M,et al.Levels of serum IL-1 beta,IL2,IL-8 and tumor necrosis factor-alpha in patients with unstable angina pectoris.Mediators Inflamm,2003,12:361-365.
  • 7Young VM,Toborek M,Yang F,et al.Effect of linoleic acid on endothelial cell inflammatory mediators.Metabolism,1998,47:566-572.
  • 8Berg K,Svindland A,Smith A J,et al.Spontaneous atherosclerosis in the proximal aorta of LPA transgenic mice on a normal diet.Atherosclerosis,2002,163:99-104.

同被引文献33

  • 1范乐明.动脉粥样硬化炎症机制的再认识[J].中国动脉硬化杂志,2005,13(3):249-253. 被引量:73
  • 2刘甲兴,郑兴,秦永文,丁继军,赵仙先,曹江.脂蛋白相关性磷脂酶A_2活性能反映冠状动脉粥样硬化病变程度[J].第二军医大学学报,2006,27(4):391-395. 被引量:31
  • 3刘甲兴,郑兴.脂蛋白相关磷脂酶A2与动脉粥样硬化[J].中国动脉硬化杂志,2006,14(3):274-276. 被引量:14
  • 4李振光,于占彩,王远臣.脂蛋白相关性磷脂酶A2与缺血性心脑血管病[J].国际脑血管病杂志,2007,15(2):102-105. 被引量:4
  • 5Ballanyne CM,Hoogeveen RC,Bang H,et al.Lipoprotein associated phosphlipmeA2,high sensitivity C reactive protein,and risk for incident coronary heart disease.Risk in Communities(ARIC)study[J].Circulation,2004,109:837-842.
  • 6Koenig W,Khuseyinova N,Lowel H,et al.Lipoprotein associated phospholipase A2 adds to risk prediction of incident:results from the 14 year follow up of a large cohort from Germany[J].Circulation,2004,110:1903-1908.
  • 7Yang EH, McConnell JP, Lennon RJ,et al. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans [ J ]. Arterioscler Thromb Vasc Biol,2006,26 : 106-111.
  • 8Khuseyinova N, Imhof A, Rothenbacher D, et al. Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflanlmation and hemostasis [ J ]. Atherosclerosis, 2005,182 : 181- 188.
  • 9Iribarren C, Gross MD, Darhinian JA, et al. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults. The CA RDIA Study[ J ]. Arterioscler Thromb Vasc Biol,2005,25:216- 221.
  • 10Brilakis ES, McConnell JP, Lennon RJ, et al. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up[ J ]. Eur Heart J ,2005,26 : 137-144.

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部